Summary:
The TRACTION-2 Trial for Focal segmental glomerulosclerosis (FSGS)
What is FSGS?
FSGS is a type of kidney disease that occurs when scar tissue develops on the parts of your kidneys that act as filters (the glomeruli). The scar tissue makes it more difficult for the filters to do their job. Instead of keeping essential proteins in your body, the injured filters allow these proteins to flow into the urine. This can lead to high levels of protein in your urine, a condition called proteinuria.
Podocytes are cells lining the kidney that, in their normal state, prevent proteinuria. Injury to, and loss of, podocytes is a central component of FSGS. Protecting podocytes from further injury, and stopping proteinuria, may help slow progression of kidney disease and potentially prevent kidney failure.
What is the purpose of this trial?
Currently, there is no approved therapy in the US to treat Focal Segmental Glomerulosclerosis (FSGS). Advances in drug therapy are key to treating FSGS in its early stages and preventing further kidney damage. The TRACTION-2 Trial is testing an investigational medication (GFB-887) that has the potential to reduce the amount of protein in urine and preserve kidney function in patients with kidney disease. If you have FSGS, this trial may be an option for you.
Who can be in the trial?
You may qualify to participate if you:
- Are 18 to 75 years of age
- Have been diagnosed or are being treated for FSGS
- Have high levels of protein in your urine (proteinuria)
The doctor running the study will discuss other eligibility criteria with you to see if you may qualify.